Details

Autor(en) / Beteiligte

• Fernández-Miranda, Consuelo
• Castellano, Gregorio
• Guijarro, Carlos
• Fernández, Inmaculada
• Schöebel, Natalia
• Larumbe, Sagrario
• Gómez-Izquierdo, Teresa
• del Palacio, Angel

Titel

Lipoprotein changes in patients with chronic hepatitis C treated with interferon-α

Ist Teil von

• The American journal of gastroenterology, 1998-10, Vol.93 (10), p.1901-1904

Ort / Verlag

Oxford: Elsevier Inc

Erscheinungsjahr

1998

Quelle

MEDLINE

Beschreibungen/Notizen

• Objective: The aim of this study was to evaluate the effects of interferon-α therapy on the lipid profile of patients with chronic hepatitis C. Methods: In 36 consecutive patients with chronic hepatitis C, fasting lipoproteins were evaluated prospectively at baseline, 1, 3 and 6 months during interferon-α therapy and 3 months after the end of treatment. Results: During interferon-α therapy, there was a progressive increase in total and very low density lipoprotein (VLDL)-triglycerides, VLDL-cholesterol and a sustained raise in apolipoprotein (apo) B. In parallel, there was a reduction in high density lipoprotein (HDL)-cholesterol and apo A1 levels. In contrast, total and low density lipoprotein (LDL)-cholesterol and lipoprotein (a) levels remained essentially unchanged during interferon-α therapy. Three patients developed chylomicronemia, two of them with severe hypertriglyceridemia, although none of them presented with pancreatitis. Chylomicronemia and severe hypertriglyceridemia were more common in patients with basal triglycerides above 200 mg/dl. Nineteen patients responded to interferon-α therapy, but their lipid profile did nor differ from that of nonresponders. Three months after the end of interferon-α therapy lipid changes subsided, although VLDL and HDL-cholesterol and apo B did not reach basal levels. Conclusion: In patients with chronic hepatitis C, interferon-α therapy is associated with an increase of total and VLDL-triglycerides, VLDL-cholesterol and apo B, and a decline of HDL-cholesterol and apo A1. The development of chylomicronemia and severe hypertriglyceridemia in some cases makes mandatory a close monitoring of triglycerides during interferon-α therapy, particularly among patients with increased triglycerides at baseline.